Business Areas

Improving the quality of our lives through state-of-the-art R&D capabilities.

Life science, with outstanding R&D competence and new drugs that have been approved by USFDA for the first time in Korea, is LG Chem’s new growth engine in the mid to long term.

We are aggressively making inroads in overseas markets and expanding pipelines for new drugs through constant investment and reinforcing R&D, with aspirations to become one of the top global pharmaceutical companies.

Sales

Sales :2022 ,2023 ,2024
2022	0.9
2023	1.2
2024	1.3

Unit : KRW trillion

2024 Technology export of rare obesity drug to U.S. company 'Rhythm Pharmaceuticals'
2023 Acquired AVEO, a US-based cancer drug company
2022 Launch of the growth hormone treatment Eutropin S PEN
2021 Established a joint venture sales corporation LG Jiansheng Life Sciences in China
2019 Established the Global Innovation Center in Boston, US
2017 Merged with
LG Life Sciences
2012 Released the first Korean diabetes drug Zemiglo
2003 1st Korean NCE approved by
USA FDA(Factive)
1996 Won the first prequalification by the WHO with Hepatitis B vaccine Euvax B
1991 Developed World’s first
4th generation Cephalosporin
1984 Established Pharmaceuticals
business division
1961 Obtained the drug manufacturing permit

Division

Primary Care Division

Specialty Care Division

Aesthetic Division

Go to the related products ▶

VISION

Toward a World-Class Innovative Drug Developer

5 or more innovative new drugs by 2030
Enhanced the quality of new drug pipeline
Invest over USD 250mil in annual R&D
Strengthening of Open innovation

Diabetes, metabolic diseases, cancer, autoimmune diseases
Expand new drug pipelines in clinical development stage

Expand new drug pipelines in clinical development stage :2024 ,2030
2024	12EA
2030	20EA

Explore Research Preclinical Clinical

Accelerate clinical developments and business growth worldwide
New tasks for global clinical development
Continued growth of AVEO's oncology business in the US

LG Chem Life Science Pipeline

Diabetes & Metabolism
Oncology & Immunology
Vaccine
Aesthetic

Preclinical(2)

LR20061 LR20061Atopic Dermatitis

해당 프로젝트 팝업
Molecule	LR20061
Stage	Preclinical
Indication	Atopic Dermatitis
Modality	Chemical
Target	Undisclosed

LR19157 LR19157Oncology

해당 프로젝트 팝업
Molecule	LR19157
Stage	Preclinical
Indication	Oncology
Modality	Chemical
Target	Undisclosed

Phase I(6)

LR19129 CUE-102Oncology

해당 프로젝트 팝업
Molecule	CUE-102
Stage	Phase 1 (by Partner)
Location summary	USA
Indication	Oncology
Modality	Biologics
Target	WT-1
Partner	Cue Biopharma

LR19125 PDC*LungNSCLC

해당 프로젝트 팝업
Molecule	PDC*Lung
Stage	Phase 1 (by Partner)
Location summary	Europe
Indication	NSCLC
Modality	Cell therapy
Target	Cancer vaccine
Partner	PDC*line Pharma

AV-380 RilogrotugCachexia

해당 프로젝트 팝업
Molecule	Rilogrotug
Stage	Preclinical
Location summary	USA
Indication	Cachexia
Modality	Biologics
Target	anti-GDF15 IgG1 mAb

AV-203 AV-203Oncology

해당 프로젝트 팝업
Molecule	AV-203
Stage	Phase 1
Location summary	USA
Indication	Oncology
Modality	Biologics
Target	Anti-ERBB3 IgG1 mAb

LR19155 LB-LR1109Oncology

해당 프로젝트 팝업
Molecule	LB-LR1109
Stage	Phase 1
Indication	Oncology
Modality	Biologics
Target	LILRB1

LR19018 LG203003NASH

해당 프로젝트 팝업
Molecule	LG203003
Stage	Phase 1
Location summary	USA
Indication	NASH
Modality	NCE
Target	DGAT-2

Phase II(4)

LR20062 aP vaccine

해당 프로젝트 팝업
Molecule	aP vaccine
Stage	Phase 2
Indication	aP vaccine
Modality	Vaccine
Target	aP vaccine

Diphtheria, Tetanus, Pertussis,Polio, Hib, HebB

LR19021 BivamelagonRare Obesity

해당 프로젝트 팝업
Molecule	Bivamelagon
Stage	Phase 2
Location summary	USA
Indication	Rare Obesity
Modality	NCE
Target	MC4R
Partner	Rhythm Pharmaceuticals (License-out)

LR19114 6 in 1 Vaccine

해당 프로젝트 팝업
Molecule	6 in 1 Vaccine
Stage	Phase 2
Indication	6 in 1 Vaccine
Modality	Vaccine
Target	6 in 1 Vaccine

Diphtheriae (D), Bordetella pertussis (wP), Clostridium tetani (T), Hepatitis B (HepB) Haemophilus influenzae type b(Hib) Vaccine-Associated Paralytic Poliomyelitis(IPV)

LR19019 ZectivimodUlcerative colitis Atopic dermatitis

해당 프로젝트 팝업
Molecule	Zectivimod
Stage	Phase 2 (by Partner)
Location summary	China
Indication	Ulcerative colitis Atopic dermatitis
Modality	NCE
Target	S1P1
Partner	TransThera (License-out)

License-out, China

Phase III(2)

TiNivo-2 Tivozanib +/- NivolumabRenal Cell Carcinoma following prior CPI

해당 프로젝트 팝업
Molecule	Tivozanib +/- Nivolumab
Stage	Phase 3
Location summary	Global
Indication	Renal Cell Carcinoma following prior CPI
Modality	Small molecule
Target	VEGFR TKI
Partner	Bristol Myers Squibb Opdivo combination

AV-299 FiclatuzumabHead and neck squamous cell carcinoma

해당 프로젝트 팝업
Molecule	Ficlatuzumab
Stage	Phase 3
Location summary	Global
Indication	Head and neck squamous cell carcinoma
Modality	Biologics
Target	Anti-HGF/c-MET IgG1 mAb

Clinical trials

NDA(2)

LR20024 Y-solution, MDRHA filler

해당 프로젝트 팝업
Molecule	Y-solution, MDR
Stage	NDA
Location summary	Europe
Indication	HA filler
Modality	HA
Target	HA

LR19094 Y-solution, ChinaHA filler

해당 프로젝트 팝업
Molecule	Y-solution, China
Stage	NDA
Location summary	China
Indication	HA filler
Modality	HA
Target	HA

Image Download 다운로드

Core Products

Eutropin

Hyruan One

Zemiglo / Zemimet SR Tab. / Zemidapa

Eucept

YVOIRE

Press Releases

LG Chem Achieves First Export Milestone for New Diabetes Combination Drug Zemidapa 2025.05.08

LG Chem Becomes First Korean Company to Enter Canadian Dermal Filler Market 2024.12.12

Video

Select

Opening of a Global Innovation Center